Redeye: AVTECH - Poised for growth 2024
Redeye provides an update subsequent AVTECH's Q3 2023 report. AVTECH came in slightly below on topline and EBITDA. However, we are still pleased with the results. The current run-rate implies our incremental revenue for 2024e is only SEK3.6m, or 9.5% convertion of the pipeline. Thus, we believe the risk/reward remains favorable at the current valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/